Advancing Lung Cancer Research
Last year saw significant progress against lung cancer, with seven new therapeutics, including two immunotherapeutics, approved by the U.S....
Category: AACR
Last year saw significant progress against lung cancer, with seven new therapeutics, including two immunotherapeutics, approved by the U.S....
It’s that time of year when we reflect on the progress we made over the past 12 months –...
During this holiday season, the AACR Foundation, like many other nonprofit organizations, administers its end-of-year appeal campaign. We urge...
This year has been a momentous year in healthcare, and, as some news outlets like Boston’s WBUR radio are...
On Nov. 16, 2015, the AACR hosted several dozen patient advocates and executives from leading pharmaceutical companies, as well...
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new anticancer therapeutics continued last week when...
Breast cancer researchers are packed up in San Antonio, eager to build on the latest information they gathered at...
Breast cancer recurrence rates were similar for postmenopausal women with estrogen receptor-positive DCIS whether they took anastrozole or tamoxifen,...
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.